Injectafer recently secured approval in the US for improvement in exercise capacity in adults with symptomatic heart failure (HF).  A significant number of chronic HF patients suffer from iron deficiency, and these patients are either not diagnosed or do not receive adequate treatment for iron deficiency. Injectafer’s approval allows potentially iron-deficient patients to better manage their symptomatic HF. In terms of iron therapies, Injectafer will continue penetrating the intravenous (IV) iron therapy market, says GlobalData, a leading data and analytics company.

Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: “Key opinion leaders interviewed by GlobalData have emphasized that iron replacement therapy can be helpful, but these therapies represent a niche market in the HF space.”

Injectafer’s FDA approval was supported by the CONFIRM-HF Phase IV trial. The trial demonstrated that over a year of treatment with ferric carboxymaltose, which rapidly improves hemoglobin levels and replenishes depleted iron stores, resulted in a significant and sustainable improvement in exercise capacity in adults with symptomatic HF. In addition, the safety profiles were consistent with the well-established safety profile of the medicine.

Jaddoo concludes: “As it is the first and only IV iron replacement therapy in the US indicated to treat iron deficiency in adult patients with HF, Injectafer is not expected to be in direct competition with other classes of drugs, as it will be used in combination with other drugs for management of HF. The drug maintained its blockbuster status in 2021.”